$MO (+1.56%)

If it were always like this.... Admittedly, this is not the rule, which $MO (+1.56%) shown here. But it's also a nice example of someone who is happy about their dividend shares.

At 1 is the closing price from 24.03.2025, yesterday on 25.03. was the ex-dividend day of € 0.95 rounded. This was also priced in immediately and led to the usual daily fluctuations, only to close at 2 at the level of the pure dividend discount. Today everything was made up again, so that in this case the dividend less taxes was cäsh in the däsch.

It's just a shame that you can't and shouldn't get used to it.

In January I decided to set up a dividend portfolio for myself. I immediately used the setback in February to end my one-year "test phase" as a stock market novice and start my long-term plan. In addition to two dividend-paying ETFs for retirement provision $XDWL (+0.92%) & $XSX7 (+1.74%) I want to build up a strong portfolio through stable dividend stocks, regular purchases and reinvestment of dividends.

I would like to take you with me on my journey and now share regular updates on the development of my portfolio.

You can find my goals and how I want to achieve them in my first post → My path to financial freedom: I'm building a dividend portfolio - goals & strategy 📈💰

(https://getqu.in/T7yDJe/)

📊 My current dividend portfolio (sorted by market capitalization):

1️⃣ $SAP (+1.32%) - Europe's largest software group with a stable dividend policy

2️⃣ $BAC (+4.71%) - One of the largest US banks with a solid payout

3️⃣ $AXP (+2.62%) - Strong brand with long-term potential

4️⃣ $ALV (+0.88%) - High dividend yield & strong financials

5️⃣ $DB1 (+1.38%) - Benefits from rising trading volumes

6️⃣ $BATS (+2.21%) - High dividend yield & stable cash flow

7️⃣ $MO (+1.56%) - Continuous dividend increases, but regulatory risks

8️⃣ $O (+1.82%) - The famous "Monthly Dividend Company" REIT

9️⃣ $INGA (+2.56%) - European bank with attractive dividend yield

I start my journey with these 9 stocks. All of them convince me and are stable stocks. I'm not doing anything here for no reason. That's why there's a good reason for every stock I buy.

If you would like to know why I chose one of the stocks, let's discuss it in the comments. I look forward to the exchange! 😊

I wish you a good start to the weekend!

#Dividendenstrategie
#FinanzielleFreiheit
#Investieren
#Börse
#Dividenden
#PassivesEinkommen
#Aktien

Volume:

Combustables: -10%

Total Oral: -1%

On!: +40%

NJOY devices: +22%

NJOY consumables : +15%

Market Share:

Marlboro: 41.7% -60bps

Copenhagen: 19.1% -440bps

Skoal: 7.6% -170bps

On!: 8.3% +150bps

NJOY: 5.5% +280bps

NJOY ACE

In the patent dispute with JUUL, the ITC rules in favor of JUUL. As a result, the import and sale of NJOY ACE is banned and NJOY ACE will be off the market from April 2025.

Combustables Volume

There is no end in sight to the ever-shrinking US cigarette market.

Oral

Copenhagen (-8.8%) and Skoal (-9.9) are now shrinking at the same rate as the cigarette market; in my opinion, these can no longer be counted among the "new" alternative growth products as once planned by Altria. On! sales figures look good, but market share can only be gained very slowly.

Conclusion

On the whole, the report is quite sobering to disappointing. The goals that were set with NJOY have now been discarded and can no longer be achieved. And statements such as "we expect the Altria's future earnings growth to be negatively impacted by further "RRP catch-up investment"." are more than disappointing for me.

For me, this shows once again that the $MO (+1.56%) Altria management is no longer what it used to be. NJOY is finally on the market and they didn't manage to check the patent situation beforehand. Cronos, JUUL and now NJOY. One can only hope that they don't screw up with On!

The Food and Drug Administration (FDA) is backing away from its previously proposed tobacco product standard to ban menthol as a characterizing flavor in cigarettes on public health grounds. The FDA argued that menthol increases the appeal of cigarettes, especially to younger audiences. The proposed ban was intended to reduce experimentation and use among youth while improving the health of current menthol cigarette smokers by encouraging smoking cessation.

The withdrawal of this proposal is seen as a positive for tobacco companies who would have faced the loss of a significant market share. In the United States, there are over 18.5 million smokers aged 12 and older who use menthol cigarettes.

The FDA action aimed to address the leading preventable cause of death and disease in the country and reduce tobacco-related deaths and illnesses associated with menthol cigarette use. The agency also hoped to improve health equity by reducing tobacco-related health disparities.

With the proposal now off the table, tobacco companies are likely to be able to continue selling menthol cigarettes without the threat of an imminent ban. This is reflected in the positive share price performance. The market reaction indicates investor relief as a significant regulatory risk for these companies has been removed.

The news is particularly relevant for British American Tobacco $BATS (+2.21%)which, along with its industry peers $MO (+1.56%)
$PM (+2.26%)
$IMB (+3.03%) may now be able to avoid the financial impact that a menthol ban would have had on sales and market share.